SC-53116 hydrochloride hydrate

≥98% (HPLC)

SC 49518 hydrate, 4-Amino-5-chloro-N-[[(1S,7aS)-hexahydro-1H-pyrrolizin-1-yl]methyl]-2-methoxy-benzamide
Empirical Formula (Hill Notation):
C16H22ClN3O2 · HCl · xH2O
Molecular Weight:
360.28 (anhydrous basis)
PubChem Substance ID:
Pricing and availability is not currently available.

Quality Level


≥98% (HPLC)



mfr. no.



, white to yellow to brown


H2O: 10 mg/mL, clear



storage temp.


SMILES string




InChI key


Related Categories


5, 25 mg in glass bottle

Biochem/physiol Actions

SC-53116 is a 5-HT4 receptor partial agonist. SC-53116 has been shown to ameliorate scopolamine-induced impairment in learning in rats at a does of 10 μg/rat i.c.v and increase population spike amplitude in the CA1 and CA3 fields of the hippocampus at the same concentration.

Features and Benefits

This compound was developed by Pfizer for Neuroscience research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®Pfizer), a collection of 90 Pfizer-developed drugs and research tools. Click here to learn more.

Legal Information

Sold for research purposes under agreement from Pfizer Inc.
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC
Pfizer is a registered trademark of Pfizer, Inc.


NONH for all modes of transport

WGK Germany


Certificate of Analysis
Certificate of Origin
Laurie B Schenkel et al.
Organic letters, 6(20), 3621-3624 (2004-09-25)
[reaction: see text] Highly diastereoselective intra- and intermolecular self-condensation reactions of N-tert-butanesulfinyl aldimines have been developed and applied to the rapid, asymmetric synthesis of trans-2-aminocyclopentanecarboxylic acid and the drug candidate SC-53116. Key to both syntheses is a novel microwave-assisted reaction...
SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.
D L Flynn et al.
Journal of medicinal chemistry, 35(8), 1486-1489 (1992-04-17)
S S Hegde et al.
Naunyn-Schmiedeberg's archives of pharmacology, 351(6), 589-595 (1995-06-01)
It is well documented that certain substituted benzamides, such as cisapride, and benzimidazolones, such as BIMU 8, enhance gastric emptying in rats. As these compounds possess 5-HT3 antagonistic and 5-HT4 agonistic properties, the precise mechanisms (5-HT3 or 5-HT4) underlying their...
P G McLean et al.
Naunyn-Schmiedeberg's archives of pharmacology, 354(4), 513-519 (1996-10-01)
The effects of chronic infusion with 5-hydroxytryptamine (5-HT, 75 micrograms/kg per hour) for 5 or 10 days in vivo on the responses of rat oesophagus, fundus and jejunum to 5-HT and partial 5-HT receptor agonists in vitro were investigated. In...
P G McLean et al.
British journal of pharmacology, 115(1), 47-56 (1995-05-01)
1. The pharmacological properties of 5-hydroxytryptamine (5-HT), the 5-HT4 receptor agonists, DAU 6236 and SC 53116 and the 5-HT4 receptor antagonist, GR 1130808, were studied in the rat oesophagus, rat ileum and human colon. 2. 5-HT relaxed the longitudinal muscle...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.